Comparing the benefits and safety of Metformin and Canthex® for treating dark skin patches in patients of Acanthosis Nigricans
Phase 4
- Conditions
- Health Condition 1: L83- Acanthosis nigricans
- Registration Number
- CTRI/2024/08/071850
- Lead Sponsor
- Rutuja Angad Shinde
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Clinically diagnosed with acanthosis nigricans and HOMAIR greater than 1.8
Exclusion Criteria
Female Patients who are pregnant and lactating.
Patients who are already taking some antidiabetic medication
Patients with renal compromise
Patients with hepatic compromise
Drug induced acanthosis nigricans
Malignant acanthosis nigricans
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome measures for effectiveness will be improvement of severity of neck lesions and neck texture which is to be measured by quantitative scale of acanthosis nigricans by Burke et alTimepoint: at the end of 3 months
- Secondary Outcome Measures
Name Time Method nilTimepoint: nil